CY1118275T1 - Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων - Google Patents
Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδωνInfo
- Publication number
- CY1118275T1 CY1118275T1 CY20161101091T CY161101091T CY1118275T1 CY 1118275 T1 CY1118275 T1 CY 1118275T1 CY 20161101091 T CY20161101091 T CY 20161101091T CY 161101091 T CY161101091 T CY 161101091T CY 1118275 T1 CY1118275 T1 CY 1118275T1
- Authority
- CY
- Cyprus
- Prior art keywords
- glucocorticoids
- glucocorticoid
- relates
- component
- designed
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000009256 replacement therapy Methods 0.000 title abstract 2
- 239000003862 glucocorticoid Substances 0.000 abstract 11
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010072079 Glucocorticoid deficiency Diseases 0.000 abstract 2
- 229960000890 hydrocortisone Drugs 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56420504P | 2004-04-22 | 2004-04-22 | |
| SE0401031A SE0401031D0 (sv) | 2004-04-22 | 2004-04-22 | A new glucocorticoid replacement therapy |
| PCT/EP2005/004400 WO2005102271A2 (en) | 2004-04-22 | 2005-04-21 | Pharmaceutical compositions for glucocorticoid replacement therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118275T1 true CY1118275T1 (el) | 2017-06-28 |
Family
ID=35197481
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101091T CY1118275T1 (el) | 2004-04-22 | 2016-10-26 | Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων |
| CY20211100191T CY1124074T1 (el) | 2004-04-22 | 2021-03-05 | Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100191T CY1124074T1 (el) | 2004-04-22 | 2021-03-05 | Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8425937B2 (https=) |
| EP (2) | EP3072507B1 (https=) |
| JP (2) | JP5149618B2 (https=) |
| CN (2) | CN1942176B (https=) |
| AU (1) | AU2005235370B2 (https=) |
| BR (1) | BRPI0510044B8 (https=) |
| CA (1) | CA2564000C (https=) |
| CY (2) | CY1118275T1 (https=) |
| DK (2) | DK1744730T3 (https=) |
| ES (2) | ES2857600T3 (https=) |
| HR (2) | HRP20161380T1 (https=) |
| HU (2) | HUE053248T2 (https=) |
| IL (2) | IL178776A (https=) |
| LT (2) | LT3072507T (https=) |
| ME (1) | ME02584B (https=) |
| MX (2) | MX344197B (https=) |
| NZ (1) | NZ585340A (https=) |
| PL (2) | PL1744730T3 (https=) |
| PT (2) | PT1744730T (https=) |
| RS (2) | RS55198B1 (https=) |
| SE (1) | SE0401031D0 (https=) |
| SG (1) | SG188081A1 (https=) |
| SI (1) | SI3072507T1 (https=) |
| WO (1) | WO2005102271A2 (https=) |
| ZA (1) | ZA200609680B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007533697A (ja) | 2004-04-22 | 2007-11-22 | デュオコート エービー | グルココルチコイド救急治療用の医薬組成物 |
| SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| EP1971312A1 (en) * | 2005-12-06 | 2008-09-24 | MonoSol Rx LLC | Topical film compositions for delivery of actives |
| FR2926722B1 (fr) * | 2008-01-25 | 2010-09-03 | Substipharm Dev | Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone |
| ES2358158T3 (es) * | 2008-07-21 | 2011-05-06 | Dr. Falk Pharma Gmbh | Formulación farmacéutica para el tratamiento del tracto digestivo superior. |
| NZ595428A (en) * | 2009-04-07 | 2013-04-26 | Duocourt Pharma Ab | Improved glucocorticoid therapy |
| PE20131024A1 (es) | 2010-05-20 | 2013-10-10 | Duocort Pharma Ab | Composiciones basadas en glucocorticoides |
| GB201119985D0 (en) * | 2011-11-19 | 2012-01-04 | Diurnal Ltd | Treatment of adrenal insufficiency |
| GB201202433D0 (en) * | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
| JP2014086673A (ja) | 2012-10-26 | 2014-05-12 | Mitsubishi Electric Corp | モノリシック集積回路 |
| JP6356684B2 (ja) | 2012-11-02 | 2018-07-11 | マレイ・アンド・プール・エンタープライゼズ・リミテッド | コルヒチン誘導体の投与による心血管イベントの処置または予防 |
| DK2986280T3 (da) * | 2013-04-16 | 2021-06-14 | Murray & Poole Entpr Ltd | Formuleringer med langvarig frigivelse af colchicin og fremgangsmåder til brug af samme |
| CA2909370A1 (en) * | 2013-04-16 | 2014-10-23 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
| GB201308933D0 (en) | 2013-05-17 | 2013-07-03 | Diurnal Ltd | Paediatric composition |
| MX348595B (es) * | 2013-08-02 | 2017-06-21 | Laboratorio Raam De Sahuayo S A De C V | Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion. |
| PT2886108T (pt) | 2013-12-23 | 2019-04-01 | Dr Falk Pharma Gmbh | Formulação farmacêutica otimizada para o tratamento de alterações inflamatórias do esófago |
| WO2016160969A1 (en) | 2015-03-30 | 2016-10-06 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
| CN107115308B (zh) * | 2016-02-23 | 2021-02-23 | 天津金耀集团有限公司 | 一种氢化可的松双相缓释片剂组合物 |
| RU2748437C2 (ru) * | 2019-10-28 | 2021-05-25 | Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) | Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера |
| FR3116439B1 (fr) * | 2020-11-26 | 2023-08-04 | Laboratoire Dielen | Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains |
| WO2026052804A1 (en) | 2024-09-06 | 2026-03-12 | Institut National de la Santé et de la Recherche Médicale | Hydrocortisone based oral dispersible film and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2260384C3 (de) * | 1972-12-09 | 1979-11-29 | Hoechst Ag, 6000 Frankfurt | Oral zu applizierendes Corticosteroid-Präparat |
| US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5314697A (en) | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| ATE253899T1 (de) | 1994-01-31 | 2003-11-15 | Yamanouchi Pharma Co Ltd | Intraoral löslicher formpressling und verfahren zu seiner herstellung |
| US5534263A (en) | 1995-02-24 | 1996-07-09 | Alza Corporation | Active agent dosage form comprising a matrix and at least two insoluble bands |
| US5976573A (en) | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| DE19718012C1 (de) | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
| US6602521B1 (en) | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
| US6500459B1 (en) | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
| US6156743A (en) | 1999-10-18 | 2000-12-05 | Whitcomb; John E. | Method of decreasing fatigue |
| AR026148A1 (es) * | 2000-01-21 | 2003-01-29 | Osmotica Argentina S A | Dispositivo osmotico con pasaje preformado que aumenta de tamano |
| AP1748A (en) * | 2001-03-13 | 2007-06-11 | Penwest Pharmaceuticals Co | Chronotherapeutic dosage forms. |
| AU2002254205B2 (en) * | 2001-03-15 | 2007-05-10 | Enteron Pharmaceuticals, Inc. | Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids |
| GB0119848D0 (en) | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| WO2003066029A2 (en) | 2002-02-07 | 2003-08-14 | Pharmacia Corporation | Pharmaceutical dosage form for mucosal delivery |
| GB0400031D0 (en) | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
| SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| JP2007533697A (ja) | 2004-04-22 | 2007-11-22 | デュオコート エービー | グルココルチコイド救急治療用の医薬組成物 |
| GB0623740D0 (en) | 2006-11-28 | 2007-01-10 | Diurnal Ltd | Treatment of disease |
| NZ595428A (en) | 2009-04-07 | 2013-04-26 | Duocourt Pharma Ab | Improved glucocorticoid therapy |
| PE20131024A1 (es) | 2010-05-20 | 2013-10-10 | Duocort Pharma Ab | Composiciones basadas en glucocorticoides |
-
2004
- 2004-04-22 SE SE0401031A patent/SE0401031D0/xx unknown
-
2005
- 2005-04-21 RS RS20160749A patent/RS55198B1/sr unknown
- 2005-04-21 HR HRP20161380TT patent/HRP20161380T1/hr unknown
- 2005-04-21 AU AU2005235370A patent/AU2005235370B2/en not_active Expired
- 2005-04-21 PL PL05735076T patent/PL1744730T3/pl unknown
- 2005-04-21 DK DK05735076.1T patent/DK1744730T3/en active
- 2005-04-21 HU HUE16169413A patent/HUE053248T2/hu unknown
- 2005-04-21 MX MX2013004889A patent/MX344197B/es unknown
- 2005-04-21 LT LTEP16169413.8T patent/LT3072507T/lt unknown
- 2005-04-21 MX MXPA06012011A patent/MXPA06012011A/es active IP Right Grant
- 2005-04-21 US US11/587,514 patent/US8425937B2/en active Active
- 2005-04-21 BR BRPI0510044A patent/BRPI0510044B8/pt not_active IP Right Cessation
- 2005-04-21 PT PT57350761T patent/PT1744730T/pt unknown
- 2005-04-21 EP EP16169413.8A patent/EP3072507B1/en not_active Expired - Lifetime
- 2005-04-21 LT LTEP05735076.1T patent/LT1744730T/lt unknown
- 2005-04-21 DK DK16169413.8T patent/DK3072507T3/da active
- 2005-04-21 NZ NZ585340A patent/NZ585340A/en not_active IP Right Cessation
- 2005-04-21 SI SI200532291T patent/SI3072507T1/sl unknown
- 2005-04-21 SG SG2013005244A patent/SG188081A1/en unknown
- 2005-04-21 PT PT161694138T patent/PT3072507T/pt unknown
- 2005-04-21 JP JP2007508863A patent/JP5149618B2/ja not_active Expired - Lifetime
- 2005-04-21 CA CA2564000A patent/CA2564000C/en not_active Expired - Lifetime
- 2005-04-21 ES ES16169413T patent/ES2857600T3/es not_active Expired - Lifetime
- 2005-04-21 CN CN2005800118623A patent/CN1942176B/zh not_active Expired - Lifetime
- 2005-04-21 ME MEP-2016-250A patent/ME02584B/me unknown
- 2005-04-21 RS RS20210233A patent/RS61501B1/sr unknown
- 2005-04-21 EP EP05735076.1A patent/EP1744730B1/en not_active Expired - Lifetime
- 2005-04-21 HU HUE05735076A patent/HUE030546T2/en unknown
- 2005-04-21 CN CN201210499801.8A patent/CN103006592B/zh not_active Expired - Lifetime
- 2005-04-21 ES ES05735076.1T patent/ES2600556T3/es not_active Expired - Lifetime
- 2005-04-21 PL PL16169413T patent/PL3072507T3/pl unknown
- 2005-04-21 WO PCT/EP2005/004400 patent/WO2005102271A2/en not_active Ceased
-
2006
- 2006-10-19 IL IL178776A patent/IL178776A/en active IP Right Grant
- 2006-11-21 ZA ZA200609680A patent/ZA200609680B/xx unknown
-
2012
- 2012-08-03 JP JP2012173158A patent/JP5681679B2/ja not_active Expired - Lifetime
- 2012-12-20 US US13/722,013 patent/US20130129823A1/en not_active Abandoned
-
2013
- 2013-07-08 IL IL227375A patent/IL227375A/en active IP Right Grant
-
2014
- 2014-04-17 US US14/255,332 patent/US10583146B2/en active Active
-
2016
- 2016-10-26 CY CY20161101091T patent/CY1118275T1/el unknown
-
2021
- 2021-03-01 HR HRP20210348TT patent/HRP20210348T1/hr unknown
- 2021-03-05 CY CY20211100191T patent/CY1124074T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118275T1 (el) | Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων | |
| Peterson et al. | Treatment of heterotopic ossification through remote ATP hydrolysis | |
| CY1121162T1 (el) | M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου | |
| ATE529125T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung | |
| CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
| ATE540129T1 (de) | Target zur therapie kognitiver behinderungen | |
| ATE495739T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
| MXPA05014166A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
| BRPI0519195A2 (pt) | composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| ATE450251T1 (de) | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung | |
| BR122020000059B8 (pt) | composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit | |
| ECSP045520A (es) | Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos | |
| CY1111263T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης | |
| ATE544460T1 (de) | Zusammensetzungen und verfahren für eine gesunde schwangerschaft | |
| UY28314A1 (es) | Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad | |
| BRPI0609393B8 (pt) | usos de um composto 11-desóxi-prostaglandina | |
| BRPI0309665B8 (pt) | método para analisar uma preparação de alfagalactosidase a | |
| CY1119317T1 (el) | Συνθεση για τοπικη εφαρμογη, χρησεις αυτης, συσκευη εφαρμογης και kit μερων | |
| BRPI0519070A2 (pt) | composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa | |
| BRPI0413404A (pt) | composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif | |
| DOP2003000621A (es) | Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa | |
| BRPI0415781A (pt) | método para o tratamento de diabetes em um paciente e kit farmacêutico | |
| BR0303912A (pt) | Composição para o condicionamento, composição para o condicionamento durável, método para o condicionamento, método para o condicionamento durável, método para o cuidado ou tratamento e kit para o cuidado, tratamento, condicionamento ou condicionamento durável |